Get the Stockscreener App
2.325
4.71%
-0.115
Protara Therapeutics Inc stock is traded at $2.325, with a volume of 47,931.
It is down -4.71% in the last 24 hours and down -34.32% over the past month.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
See More
Previous Close:
$2.44
Open:
$2.39
24h Volume:
47,931
Relative Volume:
0.04
Market Cap:
$137.40M
Revenue:
Net Income/Loss:
$-57.44M
P/E Ratio:
-1.7401
EPS:
-1.3361
Net Cash Flow:
$-56.46M
1W Performance:
+0.22%
1M Performance:
-34.32%
6M Performance:
-55.80%
1Y Performance:
-54.94%
1-Day Range:
$2.32
$2.47
1-Week Range:
$2.295
$2.61
52-Week Range:
$2.295
$7.82
Protara Therapeutics Inc Stock (TARA) Company Profile
Name
Protara Therapeutics Inc
Sector
Industry
Phone
646-844-0337
Address
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
2.325 | 137.40M | 0 | -57.44M | -56.46M | -1.3361 |
VRTX
Vertex Pharmaceuticals Inc
|
526.59 | 133.47B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.33 | 83.02B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
199.74 | 79.74B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
876.59 | 55.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.01 | 42.65B | 5.76B | 514.49M | 1.10B | 4.4813 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-26 | Initiated | JP Morgan | Overweight |
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-10-23 | Resumed | Guggenheim | Buy |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Feb-17-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Cowen | Outperform |
| Jul-29-20 | Initiated | Guggenheim | Buy |
View All
Protara Therapeutics Inc Stock (TARA) Latest News
A company developing cancer and rare-disease treatments will present at a conference Sept. 15. - Stock Titan
Protara’s TARA-002 Moves Into Pivotal Bladder Cancer Trial: What Investors Should Watch - TipRanks
Form 8K Protara Therapeutics Inc For: 11 August By Investing.com - Investing.com Nigeria
Protara (TARA) Financial Results: The Bottom-Line Figure Outpaces Its Comparison in the Latest Reading; Market Reaction: The Stock Records a Flat Reaction in the Current UpdateForward EPS Estimate - vinanet.vn
Assenagon Asset Management S.A. Sells 507,667 Shares of Protara Therapeutics, Inc. $TARA - MarketBeat
Protara Therapeutics (TARA) Climbs 0.76% to $3.97 as Consolidation Builds Ahead of Clinical CatalystsBox Spread - dars.gov.et
Protara Therapeutics (TARA) Climbs 0.76% to $3.97 as Consolidation Builds Ahead of Clinical CatalystsCharm Flow - vinanet.vn
Protara Therapeutics (NASDAQ:TARA) Downgraded to Strong Sell Rating by Wall Street Zen - MarketBeat
Protara Therapeutics (TARA) Climbs 0.76% to $3.97 as Consolidation Builds Ahead of Clinical CatalystsPoint of Control - dars.gov.et
HC Wainwright Issues Negative Forecast for TARA Earnings - MarketBeat
Protara Therapeutics, Inc. Actuals & Estimates (NASDAQ:TARA) - TradingView
Dimensional Fund Advisors LP Grows Stock Holdings in Protara Therapeutics, Inc. $TARA - MarketBeat
Janus Henderson Group (TARA holder) reports 8.4% Protara Therapeutics stake via Managed Portfolios - Stock Titan
H.C. Wainwright Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $27 - Moomoo
JonesTrading Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Protara Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Protara Therapeutics Inc Lymphatic Malformations KOL Webinar Transcript - GuruFocus
Form 8K Protara Therapeutics Inc For: 11 August By Investing.com - Investing.com South Africa
Protara Therapeutics (NASDAQ:TARA) Issues Earnings Results - MarketBeat
Protara Therapeutics (TARA) Advances Clinical Trials Amid Mixed Market Signals - GuruFocus
Protara Therapeutics, Inc. 2Q 2026: Net income $(21.7)M, EPS $(0.36) — 10-Q Summary - TradingView
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update - The Manila Times
Protara Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Protara Therapeutics Inc For: 11 August By Investing.com - Investing.com Canada
Protara Therapeutics reports Q2 2026 net loss $21.7M, cash ~$162M to fund operations into 2028 - TradingView
Protara Therapeutics: Q2 Earnings Snapshot - AOL.com
Protara Therapeutics: Q2 Earnings Snapshot - The Daily Gazette
Protara Therapeutics: Q2 Earnings Snapshot - 10TV
Press Release: Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update - Moomoo
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update - Yahoo Finance
Protara Therapeutics rated Buy with $9.96 fair value, advancing treatments for NMIBC and choline deficiency. - Pluang
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update - GlobeNewswire
Protara Posts $21.7 Million Q2 Loss as Pipeline Milestones Near | TARA Stock News - Quiver Quantitative
Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline - Seeking Alpha
Protara Therapeutics (TARA) Rises Modestly to $4.12 as Stock Consolidates Between Key LevelsDark Pool Sentiment - dars.gov.et
Protara Therapeutics (TARA) Rises Modestly to $4.12 as Stock Consolidates Between Key LevelsPercent Above MA - vinanet.vn
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Protara Therapeutics (TARA) Projected to Announce Quarterly Earnings on Monday - MarketBeat
Protara Therapeutics Inc (TARA) Balance Sheet - TradingKey
Protara Therapeutics Inc (TARA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TARA|Protara Therapeutics Inc|Price:3.975|Chg%:+0.055 - TradingKey
Protara Therapeutics Inc (TARA) Institutional Confidence - TradingKey
TARA|Protara Therapeutics Inc|Price:3.900|Chg%:-0.060 - TradingKey
TARA|Protara Therapeutics Inc|Price:4.030|Chg%:+0.010 - TradingKey
TradingKey - TradingKey
Walleye Capital LLC Boosts Position in Protara Therapeutics, Inc. $TARA - MarketBeat
What Makes Protara Therapeutics (TARA) a New Buy Stock - Yahoo Finance
Protara Therapeutics (TARA) Edges Higher, Approaches Key Resistance Amid Low VolumeLong Term Entry Picks - vinanet.vn
Protara Therapeutics Q1 2026 Earnings: Narrower Loss Amid Continued Clinical DevelopmentHigh Growth Earnings - dars.gov.et
Protara Therapeutics (TARA) Edges Higher by 2.86%, Testing Resistance Near $4.54Equal Weight ETF - dars.gov.et
Protara Therapeutics Inc Stock (TARA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Protara Therapeutics Inc Stock (TARA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| 667, L.P. | Former Affiliate |
Mar 06 '26 |
Proposed Sale |
5.85 |
38,277 |
223,920 |
0 |
| Baker Brothers Life Sciences, | Former Affiliate |
Mar 06 '26 |
Proposed Sale |
5.85 |
461,723 |
2,701,080 |
0 |
| 667, L.P. | Former Affiliate |
Mar 04 '26 |
Proposed Sale |
6.26 |
35,173 |
220,151 |
0 |
| Baker Brothers Life Sciences, | Former Affiliate |
Mar 04 '26 |
Proposed Sale |
6.26 |
424,125 |
2,654,641 |
0 |
| 667, L.P. | Former Affiliate |
Feb 25 '26 |
Proposed Sale |
5.81 |
78,716 |
457,046 |
0 |
| Baker Brothers Life Sciences, | Former Affiliate |
Feb 25 '26 |
Proposed Sale |
5.81 |
947,479 |
5,501,316 |
0 |
| 667, L.P. | Former Affiliate |
Feb 24 '26 |
Proposed Sale |
6.04 |
26,755 |
161,584 |
0 |
| Baker Brothers Life Sciences, | Former Affiliate |
Feb 24 '26 |
Proposed Sale |
6.04 |
322,039 |
1,944,922 |
0 |
7.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):